Budd Chiari syndrome (BCS) is a diverse disease with regard to the site of obstruction, the predisposing thrombophilic disorders and clinical presentation across the Asia-Pacific region. The hepatic vein ostial stenosis and short segment thrombosis are common in some parts of Asia-Pacific region, while membranous obstruction of the vena cava is common in some and complete thrombosis of hepatic veins in others. Prevalence of myeloproliferative neoplasms and other thrombophilic disorders in BCS varies from region to region and with different sites of obstruction. This heterogeneity also raises several issues and dilemmas in evaluation and approach to management of a patient with BCS. The opportunity to recanalize hepatic vein in patients with hepatic vein ostial stenosis or inferior vena cava stenting or pasty among those membranous obstruction of the vena cava is a unique opportunity in the Asia–Pacific region to restore hepatic outflow closely mimicking physiology. In order to address these issues arising out of the diversity as well as the unique features in the region, the Asia Pacific Association for Study of Liver has formulated these guidelines for clinicians.

Budd Chiari 综合征 (BCS) 是一种就阻塞部位、诱发血栓形成性疾病和整个亚太地区的临床表现而言的多种疾病。亚太地区部分地区常见肝静脉口狭窄和短段血栓形成，部分地区常见腔静脉膜性阻塞，部分地区常见肝静脉完全性血栓形成。BCS 中骨髓增生性肿瘤和其他血栓形成性疾病的患病率因地区和阻塞部位不同而异。这种异质性还在 BCS 患者的评估和管理方法中提出了几个问题和困境。为肝静脉口狭窄或下腔静脉支架置入术或腔静脉膜性阻塞患者的肝静脉再通提供了机会，这在亚太地区是一个独特的机会，可以恢复与生理学密切相关的肝流出。为了解决因该地区的多样性和独特性而产生的这些问题，亚太肝脏研究协会为临床医生制定了这些指南。